With aging, diabetes, obesity, and menopause status were risk factors for osteoporotic and bone fractures, thus it is hard to conclude the association between DPP4 inhibitors and bone metabolism from the current clinical evidence. Here, DPP4 is linked to obesity due to melanocortin 4 receptor deficiency.